Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Chinese Patent Office
Boehringer Ingelheim
Cantor Fitzgerald
Teva
McKesson
Harvard Business School
UBS
Federal Trade Commission

Generated: June 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203791

« Back to Dashboard

NDA 203791 describes SITAVIG, which is a drug marketed by Epi Hlth and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug. Additional details are available on the SITAVIG profile page.

The generic ingredient in SITAVIG is acyclovir. There are fifty-six drug master file entries for this compound. Seventy-three suppliers are listed for this compound. Additional details are available on the acyclovir profile page.
Summary for 203791
Tradename:SITAVIG
Applicant:Epi Hlth
Ingredient:acyclovir
Patents:3
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details
Pharmacology for NDA: 203791
Ingredient-typeNucleoside Analog
Mechanism of ActionDNA Polymerase Inhibitors
Medical Subject Heading (MeSH) Categories for 203791
Suppliers and Packaging for NDA: 203791
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SITAVIG acyclovir TABLET;BUCCAL 203791 NDA Cipher Pharmaceuticals US LLC 68712-049 N 68712-049-02
SITAVIG acyclovir TABLET;BUCCAL 203791 NDA EPI Health, Inc 71403-049 N 71403-049-01

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;BUCCALStrength50MG
Approval Date:Apr 12, 2013TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jun 16, 2030Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF HERPES LABIALIS
Patent:➤ Try a Free TrialPatent Expiration:Jun 3, 2027Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF HERPES LABIALIS
Patent:➤ Try a Free TrialPatent Expiration:Mar 23, 2027Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF HERPES LABIALIS

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Daiichi Sankyo
McKinsey
AstraZeneca
Moodys
Chubb
Express Scripts
Citi
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.